142 related articles for article (PubMed ID: 17491025)
1. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides.
Oueslati M; Hermosilla R; Schönenberger E; Oorschot V; Beyermann M; Wiesner B; Schmidt A; Klumperman J; Rosenthal W; Schülein R
J Biol Chem; 2007 Jul; 282(28):20676-85. PubMed ID: 17491025
[TBL] [Abstract][Full Text] [Related]
2. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway.
Hermosilla R; Oueslati M; Donalies U; Schönenberger E; Krause E; Oksche A; Rosenthal W; Schülein R
Traffic; 2004 Dec; 5(12):993-1005. PubMed ID: 15522100
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
4. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism.
Robben JH; Sze M; Knoers NV; Deen PM
Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275
[TBL] [Abstract][Full Text] [Related]
5. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
6. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
[TBL] [Abstract][Full Text] [Related]
7. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.
Morello JP; Salahpour A; Petäjä-Repo UE; Laperrière A; Lonergan M; Arthus MF; Nabi IR; Bichet DG; Bouvier M
Biochemistry; 2001 Jun; 40(23):6766-75. PubMed ID: 11389590
[TBL] [Abstract][Full Text] [Related]
8. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
9. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
Schoneberg T; Yun J; Wenkert D; Wess J
EMBO J; 1996 Mar; 15(6):1283-91. PubMed ID: 8635461
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
Mouillac B; Mendre C
Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
[TBL] [Abstract][Full Text] [Related]
11. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
[TBL] [Abstract][Full Text] [Related]
12. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
15. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
16. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus.
Postina R; Ufer E; Pfeiffer R; Knoers NV; Fahrenholz F
Mol Cell Endocrinol; 2000 Jun; 164(1-2):31-9. PubMed ID: 11026555
[TBL] [Abstract][Full Text] [Related]
17. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
Oksche A; Schülein R; Rutz C; Liebenhoff U; Dickson J; Müller H; Birnbaumer M; Rosenthal W
Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
[TBL] [Abstract][Full Text] [Related]
19. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
Wüller S; Wiesner B; Löffler A; Furkert J; Krause G; Hermosilla R; Schaefer M; Schülein R; Rosenthal W; Oksche A
J Biol Chem; 2004 Nov; 279(45):47254-63. PubMed ID: 15319430
[TBL] [Abstract][Full Text] [Related]
20. Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors.
Schwieger I; Lautz K; Krause E; Rosenthal W; Wiesner B; Hermosilla R
Mol Pharmacol; 2008 Mar; 73(3):697-708. PubMed ID: 18048502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
